H.C. Wainwright raised the firm’s price target on Pacira (PCRX) to $65 from $48 and keeps a Buy rating on the shares. The firm believes the Street is “wildly overestimating” the company’s Exparel generic risk and “dramatically underpricing” Pacira shares. It sees a “three-bagger” potential in the stock “with non-heroic assumptions.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Closing Bell Movers: Levi Strauss up 8% on earnings, futures find footing
- Pacira Pharmaceuticals Settles Patent Litigation with Fresenius
- Pacira announces settlement of U.S. patent litigation for Exparel
- Pacira announces first patient dosed in Phase 2 ASCEND study of PCRX-201
- Biotech stocks slide as Marks resignation seen being negative for sector